Genome-wide association studies (GWAS) have uncovered a link between a higher risk of AD and variations in the genes encoding for triggering receptor expressed on myeloid cells 2 (TREM2) [50,51] or the myeloid cell surface antigen CD33 [52,53,54]. This evidence concerns the gene CD33 and Alzheimer disease.